BUY FINANZFOKUS Conviction3/5 Analysis quality70/100 now
The YouTuber suggests IQVIA, trading 42.5% below its recent high, as a buy. The company is a market leader in pharmaceutical research outsourcing, benefiting from increasing drug development and regulatory complexity. Despite current slow revenue growth, IQVIA confirmed 4-7% revenue growth for 2025 and analysts expect 9% annual earnings growth. The stock is considered not expensive with a forward P/E and Price to FCF of 12.8, but investors should monitor its high debt.
“Auch dieses Unternehmen wird aktuell 42,5% unter dem jüngsten hoch gehandelt, obwohl das Unternehmen als Marktführer in einem sehr interessanten Markt aktiv ist und stark vom Outsourcing Trend in der Pharmaforschung profitieren könnte.” — ▶ 4:30